Skip to content

US · ASPI · CHEMICALS

ASP Isotopes Inc. Common Stock (ASPI) intrinsic value and stock valuation

$1.10as of 2026-11-21 · Mkt cap 336.55M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ASP Isotopes Inc. Common Stock DCF and intrinsic value

InvestorsCraft values ASPI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ASPI’s statements →

ASP Isotopes Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Basic Materials · Chemicals Dallas, TX 75201 aspisotopes.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$23.9M+1.1% 5y CAGRd
20192025
Net income
-$-175.09M
20192025
Free cash flow
-$-47.43M
20212025
Total equity
$262.9M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$23.9M$4.14M$430K$0.00$0.00
Operating income-$-57.19M-$-26.35M-$-16.04M-$-5.1M-$-2.61M
Net income-$-175.09M-$-32.33M-$-16.29M-$-4.95M-$-2.61M
EPSd-$-2.11M-$-580.74K-$-492.59K-$-137.84K-$-75.96K
Operating cash flow-$-37.78M-$-16.7M-$-5.41M-$-2.94M-$-580K
Capital expenditure-$-9.65M-$-11.37M-$-2.33M-$-4.47M-$-2.99M
Free cash flow-$-47.43M-$-28.07M-$-7.74M-$-7.41M-$-3.57M
Total assets$512.9M$94.4M$30.2M$12.5M$7.14M
Total debt$216M$37.8M$2.14M$820K$930K
Net debt-$-69.6M-$-24.14M-$-5.77M-$-1.57M-$-2.03M
Total equity$262.9M$51.2M$18.8M$9.82M$6M
Cash and short-term investments$333.3M$61.9M$7.91M$2.39M$2.95M
Income statement
20252024202320222021
Revenue$23.9M$4.14M$430K$0.00$0.00
Cost of revenue$20.4M$2.54M$290K$0.00$20K
Gross profit$3.4M$1.6M$140K$0.00-$-20K
Research and development expenses$12.4M$3.14M$760K$1.27M$40K
Selling, general and administrative expenses$48.2M$24.8M$15.4M$3.83M$2.55M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$60.6M$28M$16.2M$5.1M$2.59M
Cost and expenses$81M$30.5M$16.5M$5.1M$2.61M
Interest income$6.79M$1.24M$10K$0.00$0.00
Interest expense$570K$260K$120K$0.00$0.00
Depreciation and amortization$1.91M$470K$40K$70K$20K
Ebitda-$-157.07M-$-31.58M-$-16.14M-$-4.87M-$-2.59M
Operating income-$-57.19M-$-26.35M-$-16.04M-$-5.1M-$-2.61M
Total other income/expenses, net-$-102.37M-$-5.96M-$-260K$150K$0.00
Income before tax-$-159.56M-$-32.31M-$-16.3M-$-4.95M-$-2.61M
Income tax expense$280K$110K-$-10K$0.00$0.00
Net income-$-175.09M-$-32.33M-$-16.29M-$-4.95M-$-2.61M
Weighted average shares outstanding$83M$55.7M$33.1M$35.9M$34.4M
Weighted average diluted shares outstanding$83M$55.7M$33.1M$35.9M$34.4M
Balance sheet
20252024202320222021
Cash and short-term investments$333.3M$61.9M$7.91M$2.39M$2.95M
Net receivables$51.7M$730K$940K$0.00$0.00
Inventory$8.49M$70K$0.00$0.00$0.00
Total current assets$398.1M$65.7M$10.5M$3.3M$3.22M
Property, plant and equipment, net$35M$23.5M$12M$9.05M$3.92M
Goodwill and intangible assets$10.1M$3.17M$3.27M$0.00$0.00
Long-term investments$49M$0.00$0.00$0.00$0.00
Total non-current assets$114.7M$28.6M$19.7M$9.19M$3.92M
Total assets$512.9M$94.4M$30.2M$12.5M$7.14M
Accounts payable$5.75M$1.02M$1.11M$1.35M$60K
Short-term debt$13.6M$1.62M$870K$80K$80K
Deferred revenue$880K$880K$880K$0.00$0.00
Total current liabilities$32.7M$7.06M$5.67M$1.94M$300K
Long-term debt$202.3M$36.1M$1.27M$740K$840K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$217.3M$41.9M$5.68M$740K$840K
Capital lease obligations$1.53M$1.93M$1.67M$790K$880K
Total liabilities$250M$43.2M$11.4M$2.68M$1.14M
Common stock$1.12M$720K$490K$360K$210K
Retained earnings-$-231.26M-$-56.17M-$-23.84M-$-7.55M-$-2.61M
Accumulated other comprehensive income (loss)$2.54M-$-2.16M-$-920K$260K$20K
Total equity$262.9M$51.2M$18.8M$9.82M$6M
Total investments$96.8M$0.00$0.00$0.00$0.00
Total debt$216M$37.8M$2.14M$820K$930K
Net debt-$-69.6M-$-24.14M-$-5.77M-$-1.57M-$-2.03M
Cash flow statement
20252024202320222021
Net income-$-159.84M-$-32.42M-$-16.29M-$-4.95M-$-2.61M
Depreciation and amortization$1.91M$471.4B$40K$70K$20K
Stock-based compensation$16M$8.56M$8.74M$2M$0.00
Change in working capital-$-3.63M-$-2.62M$1.16M$30K-$-240K
Accounts receivable-$-450K-$-510K$240K$0.00$0.00
Inventory-$-320K-$-70K$0.00$0.00$0.00
Accounts payable$780K-$-880K-$-220K$570K$60K
Net cash provided by operating activities-$-37.78M-$-16.7M-$-5.41M-$-2.94M-$-580K
Investments in property, plant and equipment-$-9.65M-$-11.37M-$-2.33M-$-4.47M-$-2.99M
Acquisitions, net$25.4M$0.00-$-120K$0.00$0.00
Net cash used for investing activities-$-90M-$-11.37M-$-2.45M-$-4.47M-$-2.99M
Common stock issued$307.1M$53.1M$14.1M$8.12M$6.45M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-2.78T$0.00$0.00$0.00
Net cash used for financing activities$350.8M$82.5M$13.4M$6.64M$6.5M
Net change in cash$223.7M$54M$5.52M-$-560K$2.93M
Cash at end of period$285.6M$61.9M$7.91M$2.39M$2.95M
Operating cash flow-$-37.78M-$-16.7M-$-5.41M-$-2.94M-$-580K
Capital expenditure-$-9.65M-$-11.37M-$-2.33M-$-4.47M-$-2.99M
Free cash flow-$-47.43M-$-28.07M-$-7.74M-$-7.41M-$-3.57M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ASP Isotopes Inc. Common Stock

        ASP Isotopes Inc. is an emerging advanced materials company, currently in its pre-commercial stage. This firm is dedicated to the comprehensive management of isotopes, encompassing their creation, dissemination, promotion, and eventual sale. The company's developmental portfolio includes Molybdenum-100, a non-radioactive isotope designed for medical applications, alongside Carbon-14 and Silicon-28. Furthermore, ASP Isotopes is involved with Uranium-235, a specific uranium isotope considered crucial for the carbon-free energy sector. Established in 2021, the company maintains its headquarters in Boca Raton, Florida.

        CEO
        Paul Elliot Mann
        Employees
        271
        Beta
        3.52

        Explore

        Frequently asked questions

        What is the intrinsic value of ASP Isotopes Inc. Common Stock (ASPI)?

        InvestorsCraft does not currently publish an intrinsic value for ASPI. How the IC value is calculated.

        Is ASPI undervalued?

        InvestorsCraft does not publish an undervaluation signal for ASPI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.